AbbVie

Trial and FDA signals

• New trial + clinical hiring Started a Phase 3 trial (NCT07772492, actual start Aug 24, 2026) (+12 other new trials); 73 clinical-operations roles open. ClinicalTrials.gov NCT07772492 (Aug 24, 2026)
  Evidence (13 events)

  • Aug 24, 2026 · ClinicalTrials.gov NCT07772492
    leadSponsor.name='AbbVie'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-24,type:ACTUAL}; studyFirstPostDate=2026-08-19; briefTitle='A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata'
  • Aug 19, 2026 · ClinicalTrials.gov NCT07794878
    leadSponsor.name='AbbVie'; phases=['PHASE3']; overallStatus=RECRUITING; startDateStruct={date:2026-08-19,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Fol'
  • Sep 1, 2026 · ClinicalTrials.gov NCT07744126
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-01,type:ACTUAL}; studyFirstPostDate=2026-08-04; briefTitle='A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembroliz'
  • Aug 17, 2026 · ClinicalTrials.gov NCT07769502
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-17,type:ACTUAL}; studyFirstPostDate=2026-08-18; briefTitle='A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Particip'
  • Aug 4, 2026 · ClinicalTrials.gov NCT07752979
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-08-04,type:ACTUAL}; studyFirstPostDate=2026-08-07; briefTitle='Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities'
  • Jul 31, 2026 · ClinicalTrials.gov NCT07697456
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-31,type:ACTUAL}; studyFirstPostDate=2026-07-13; briefTitle="Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis"
  • Jul 22, 2026 · ClinicalTrials.gov NCT07730554
    leadSponsor.name='AbbVie'; phases=['PHASE2']; overallStatus=ACTIVE_NOT_RECRUITING; startDateStruct={date:2026-07-22,type:ACTUAL}; studyFirstPostDate=2026-07-28; briefTitle='A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Par'
  • Sep 14, 2026 · ClinicalTrials.gov NCT07807956
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-14,type:ACTUAL}; studyFirstPostDate=2026-09-08; briefTitle='A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With '
  • Aug 26, 2026 · ClinicalTrials.gov NCT07843693
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-26,type:ACTUAL}; studyFirstPostDate=2026-09-28; briefTitle='A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers'
  • Aug 20, 2026 · ClinicalTrials.gov NCT07071532
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-20,type:ACTUAL}; studyFirstPostDate=2025-07-17; briefTitle='A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With B'
  • Aug 10, 2026 · ClinicalTrials.gov NCT07756580
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-08-10,type:ACTUAL}; studyFirstPostDate=2026-08-10; briefTitle='A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar'
  • Jul 28, 2026 · ClinicalTrials.gov NCT07736638
    leadSponsor.name='AbbVie'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-28,type:ACTUAL}; studyFirstPostDate=2026-07-30; briefTitle='A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants'
  • Sep 9, 2026 · ClinicalTrials.gov NCT07794891
    leadSponsor.name='AbbVie'; phases=['PHASE4']; overallStatus=RECRUITING; startDateStruct={date:2026-09-09,type:ACTUAL}; studyFirstPostDate=2026-08-31; briefTitle='Study to Assess Participant Satisfaction After Jawline and Neck Treatment'
• Drug approval + hiring FDA novel approval for JUVMO (NDA 220415, Sep 25, 2026; +1 other approval); 585 manufacturing/quality or commercial roles open. FDA NDA 220415 (Sep 25, 2026)
  Evidence (2 events)

  • Sep 25, 2026 · FDA NDA 220415
    openFDA drugsfda: application_number=NDA220415; sponsor_name='ABBVIE'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260925; submission_class_code=TYPE 1; brand_name=['JUVMO', 'JUVMO (COPACKAGED)']
  • May 27, 2026 · FDA BLA 761460
    openFDA drugsfda: application_number=BLA761460; sponsor_name='ABBVIE INC'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260527; submission_class_code=TYPE 1; brand_name=['DECNUPAZ']
• FDA complete response letter Received an FDA complete response letter (BLA 761459, letter dated Apr 22, 2026); 1155 roles open. FDA BLA 761459 (Apr 22, 2026)
  Evidence (1 event)

  • Apr 22, 2026 · FDA BLA 761459
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE AbbVie Inc. Attention: Felipe Martins Associate Director, Regulatory Affairs Irvine, CA (street omitted) Dear Felipe Martins: Please refer to your biologics license applicatio

Job counts as of Oct 18, 2026. All trial and FDA signals